The 14th Annual Business of Biosimilars Agenda Is Now Available!

With Biosimilar development interest growing and the first approved monocolonal antibody in Europe this past July it will only be a matter of time before the first Biosimilar application is submitted in the US. Biosimilar market penetration is expected to grow exponentially. Are you prepared to develop a biosimilar strategy that avoids wasting time and money to be the first to market?

The 14th Annual Business of Biosimilars provides insights from market leaders including Teva, Mylan, Hospira, Sandoz, Momenta, and Boehringer Ingelheim on choosing the best pathway for the development, approval and market access of a biosimilar product. The is the only event out there that provides a unique multidisciplinary approach with a one-stop shop for all relevant topics related to Biosimilar development and market access.

Highlights include:

• THE US BIOSIMILAR LANDSCAPE
• THE GROWING GLOBAL BIOSIMILAR MARKET
• ANALYTICAL CHARACTERIZATION
• BIOSIMILAR POLICY MAKING
• MATCHING A REFERENCE PRODUCT
• CLINICAL DEVELOPMENT
• PARTNERSHIPS

To learn more, download our full agenda.

The 14th Annual Business of Biosimilars will take place October 15-17, 2012 in Boston, MA. As a reader of the Business of Biosimilars blog, you’ll receive 15% off when you use code XP1886BLOG to register. Have any questions about the event? Feel free to contact Kate Devery at kdevery@iirusa.com or visit the webpage.

Cheers,
The Business of Biosimilars Team

Business of Biosimilars Webpage
Join our Linkedin Group
Follow Us On Twitter

Share this article with your social network, just click below to share now!

Share |